One patient (P21) had AML1::ETO positive with system mastocytosis and showed the presence of persistent low-copy AML::ETO fusion gene (range: 0.00438–0.00017) post transplantation even after administration of midostaurin and avapritinib. This evidence concerns the gene RUNX1 and acute myeloid leukemia.